{
  "docId": "019de073-7cac-75f7-8c4d-c1df42c29745",
  "docSlug": "674201d8cef93b1820f78aa5772cd90f",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 36,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The table highlights DMX-1002's unique profile compared to withdrawal support and maintenance therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/33",
  "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745",
  "deckJsonHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745.json",
  "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Current standard of care for OUD is medication therapy, requiring opioid substitutes that carry significant side effects. Current strategies for withdrawal support have high rates of relapse.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8246037f-f69a-495e-8d33-16a5bddade25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.26,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: GlobalData, Evaluate Pharma (both as of 2021). (1) Current Standard of Care. (2) Rarely used given high rates of relapse. Used primarily in institutional or penitentiary settings",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc0b025b-80f1-46f5-8ecf-cbf3e20549be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.7,
        "x": 0.26,
        "y": 0.21
      },
      "kind": "table",
      "text": "Comparison matrix of DMX-1002 vs Clonidine, Lofexidine, Methadone, Buprenorphine, Naltrexone across 5 clinical criteria.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74a96041-5945-455e-aa5a-f65a5f896376",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "title",
      "text": "DMX-1002 could potentially become a paradigm-shifting therapy for Opioid Use Disorder",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e5a59ea-140b-439d-8d78-6c98c75cdb0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.68,
        "x": 0.27,
        "y": 0.08
      },
      "kind": "title",
      "text": "DMX-1002 has the potential to become the first & best in-class treatment for OUD, minimizing risk of relapse",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5df69c88-da13-4237-bbc5-cf9c0689d200",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "62411f9c-fa64-44e3-905d-0ca9bf69e445",
      "evidence": "Although not explicitly a 2x2 matrix, the comparison table across 5 clinical criteria could be argued to instantiate a matrix tool, but the evidence is not strong.",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "ee4b92da-e72a-46a9-82e0-d689a5a53b4b",
      "evidence": "The slide uses a structured grid to compare product features against competitors.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}